Pfizer (NYSE:PFE) js teaming up with Atavistik Bio, leveraging the smaller company's AMPS platform to develop precision allosteric therapeutics. The focus: Tackling two undisclosed, Pfizer-designated targets that could revolutionize treatment in oncology and beyond. While the financials are not disclosed, Pfizer has the option to license these programs once the research phase concludes, highlighting just how high the stakes are.
Atavistik Bio is bringing its game with the AMPS platform, described as a highly integrated discovery engine that unlocks functional cryptic pockets across a broad range of target classes. CEO Bryan Stuart emphasized, Allostery holds the key to targeting disease-causing proteins and delivering highly selective, better tolerated, and more effective therapies. The deal is also a boost for Atavistik's own pipeline, with its lead oncology candidate, ATV-1601, anticipated to enter clinical trials in early 2025.
https://finance.yahoo.com/news/pfizer-joins-forces-atavistik-bio-163824799.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.